Research programme: malaria therapeutics - Eisai/Medicines for Malaria Venture/St. Jude Children's Research Hospital

Drug Profile

Research programme: malaria therapeutics - Eisai/Medicines for Malaria Venture/St. Jude Children's Research Hospital

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator St. Jude Childrens Research Hospital
  • Developer Eisai Co Ltd; Medicines for Malaria Venture; St. Jude Childrens Research Hospital
  • Class Isoquinolines; Small molecules
  • Mechanism of Action Calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Malaria in USA (PO)
  • 30 May 2017 Eisai and Charles River Laboratories extend collaboration to develop next-generation anti-malaria therapeutics
  • 15 Feb 2016 Eisai Co Ltd and Charles River Laboratories collaborate to develop Malaria therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top